N. N. Alontseva
N. N. Alontseva has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- E. A. Shcheglov
Petrozavodsk State University
3 shared publications
Latest Publications
- Open Access
- 7 June 2026
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 23 (1) , 98-111
Joint osteoarthritis: Is there something we can do without a scalpel and a pill?
Osteoarthritis oflarge joints, including knee osteoarthritis, is one of the most common diseases. Pain is one of the main symptoms of knee osteoarthritis (KOA). Itleads to a decrease in quality oflife for patients. Despite undeniable advances in both surgical and medical treatments, this problem remains far from resolved. As a result of searching the PubMed, Web of Science, Scopus, Cochrane Library and eLIBRARY.RU electroniclibrary databases, 99 publications were selected from the period from 1999 to 2025, including data from randomized controlled trials,longitudinal and cohort studies, practical and clinical guidelines. This article focuses on non-pharmacological treatments for KOA, specifically the use of specialized braces, orthoses, and insoles. Current data on these devices effectiveness in osteoarthritis treatment are presented. The use of braces and orthoses helps relieve pressure on the knee joint, reduce pain, improve quality oflife, and accelerate rehabilitation after surgery. Comparative results of orthosis and brace use are analyzed. Wedge-shaped insoles should be an important element of treatment for patients with KOA. They can serve both as a preventative measure for the osteoarthritis development and as a treatment method for slowing the progression of existing disease. Furthermore, wedge-shaped insoles help improve the musculo-venous pump function and normalize venous outflow from thelimb, which is extremely important given the currently available data on the role of chronic venous disease in the development and progression of osteoarthritis. Therefore, biomechanical devices should be a mandatory component of the treatment of patients with knee osteoarthritis.
- 7 June 2026
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 23 (1) , 98-111
Open AccessJoint osteoarthritis: Is there something we can do without a scalpel and a pill?
Osteoarthritis oflarge joints, including knee osteoarthritis, is one of the most common diseases. Pain is one of the main symptoms of knee osteoarthritis (KOA). Itleads to a decrease in quality oflife for patients. Despite undeniable advances in both surgical and medical treatments, this problem remains far from resolved. As a result of searching the PubMed, Web of Science, Scopus, Cochrane Library and eLIBRARY.RU electroniclibrary databases, 99 publications were selected from the period from 1999 to 2025, including data from randomized controlled trials,longitudinal and cohort studies, practical and clinical guidelines. This article focuses on non-pharmacological treatments for KOA, specifically the use of specialized braces, orthoses, and insoles. Current data on these devices effectiveness in osteoarthritis treatment are presented. The use of braces and orthoses helps relieve pressure on the knee joint, reduce pain, improve quality oflife, and accelerate rehabilitation after surgery. Comparative results of orthosis and brace use are analyzed. Wedge-shaped insoles should be an important element of treatment for patients with KOA. They can serve both as a preventative measure for the osteoarthritis development and as a treatment method for slowing the progression of existing disease. Furthermore, wedge-shaped insoles help improve the musculo-venous pump function and normalize venous outflow from thelimb, which is extremely important given the currently available data on the role of chronic venous disease in the development and progression of osteoarthritis. Therefore, biomechanical devices should be a mandatory component of the treatment of patients with knee osteoarthritis.
- Open Access
- 9 June 2025
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 22 (1) , 59-69
The role of the micronized purified flavonoid fraction drug in lower extremities chronic vein diseases treatment
Chronic venous diseases of the lower extremities, including varicose veins, are one of the most common pathologies in modern society, affecting up to 73% of women and up to 56% of men. Despite significant advances in surgical treatment, the role of conservative therapy in the treatment of this disease does not diminish. The main group of drugs used in the conservative treatment of venous pathology are the so-called phlebotropic drugs, which are a fairly diverse group of medications of both natural and synthetic origin. One of the leading places among phlebotropic drugs is occupied by micronized purified flavonoid fraction, which is a venoactive drug consisting of diosmin 900 mg and flavonoids, in terms of hesperidin 100 mg. The effectiveness of micronized purified flavonoid fraction in relation to venous symptoms, including pain, heaviness, edema, trophic disorders and others has been demonstrated in many studies. When using MPFF, venous trophic ulcers healed faster and more frequently than in the control group without the drug. The drug was effective in patients who received invasive treatment for varicose veins, both sclerotherapy and open and endovascular interventions. The drug also proved itself in patients with various comorbid disorders, such as phlebogonarthrosis. There is a significant amount of data demonstrating the effectiveness of MPFF in pelvic varicose veins. Currently, in addition to the original drug, there are 4 generics on the market, to which, according to the current point of view, the effects proven in the study of the original drug cannot be transferred. However, the drug Detravenol in a comparative study demonstrated the same efficacy and safety profile as the original drug. This gives our patients the opportunity to choose between the original and the reproduced drug.
- 9 June 2025
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 22 (1) , 59-69
Open AccessThe role of the micronized purified flavonoid fraction drug in lower extremities chronic vein diseases treatment
Chronic venous diseases of the lower extremities, including varicose veins, are one of the most common pathologies in modern society, affecting up to 73% of women and up to 56% of men. Despite significant advances in surgical treatment, the role of conservative therapy in the treatment of this disease does not diminish. The main group of drugs used in the conservative treatment of venous pathology are the so-called phlebotropic drugs, which are a fairly diverse group of medications of both natural and synthetic origin. One of the leading places among phlebotropic drugs is occupied by micronized purified flavonoid fraction, which is a venoactive drug consisting of diosmin 900 mg and flavonoids, in terms of hesperidin 100 mg. The effectiveness of micronized purified flavonoid fraction in relation to venous symptoms, including pain, heaviness, edema, trophic disorders and others has been demonstrated in many studies. When using MPFF, venous trophic ulcers healed faster and more frequently than in the control group without the drug. The drug was effective in patients who received invasive treatment for varicose veins, both sclerotherapy and open and endovascular interventions. The drug also proved itself in patients with various comorbid disorders, such as phlebogonarthrosis. There is a significant amount of data demonstrating the effectiveness of MPFF in pelvic varicose veins. Currently, in addition to the original drug, there are 4 generics on the market, to which, according to the current point of view, the effects proven in the study of the original drug cannot be transferred. However, the drug Detravenol in a comparative study demonstrated the same efficacy and safety profile as the original drug. This gives our patients the opportunity to choose between the original and the reproduced drug.
- Open Access
- 19 November 2022
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 19 (2) , 111-118
Chronic vein insufficiency correction in patients with lower extremities varicosity and knee osteoarthritis
Introduction. Chronic vein diseases in general and varicose veins of the lower extremities in particular represent a serious medical and social problem.The aim was to study the influence of the therapy of venous outflow disorders on the treatment results of osteoarthritis of the knee joints in patients with varicose veins in combination with osteoarthritis of the knee joints.Materials and methods. The study included 105 patients with varicose veins combined with knee osteoarthritis who had previously received treatment for osteoarthritis of the knee joints but had not received or had received extremely irregular therapy for varicose veins. The follow-up period for the patients was 12 months. The patients underwent the first course of phlebotropic drugs for 2 months from the start of the study. Then this course was repeated twice at 3-month intervals. The standard phlebotropic drug was a micronized purified flavonoid fraction. Compression knitwear was recommended in all patients. Class 2 stockings or tights with an ankle pressure of 23–32 mmHg were used in the vast majority of cases. Treatment of osteoarthritis included the use of nonsteroidal anti-inflammatory drugs, disease-modifying agents (chondroitin sulfate, glucosamine sulfate), and physical therapy.Results. The VCSS scale reduced the degree of chronic venous insufficiency in the clinical group. At inclusion in the study, the average score in the clinical group was 7.1 ± 1.9, after 6 months the result was 6.1 ± 1.5, and after 12 months – 6.0 ± 1.2 points. In the control group, where patients did not receive therapy for varicose veins, there were no dynamics. The results of joint syndrome against the background of correction of venous outflow disturbances – decrease of Leken and WOMAC index values, decrease of pain syndrome according to the visual analogue scale. All this led to a decrease in the patients' need for taking analgesics.Conclusions. Out of 100 patients with joint pathology, 68 patients were diagnosed with varicose veins. These diseases aggravate each other, but we can assume that the venous pathology is primary. A vicious circle is set in motion – progression of osteoarthritis due to the disturbances of venous outflow, and varicosity due to the deterioration of muscular-venous pump functioning.
- 19 November 2022
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 19 (2) , 111-118
Open AccessChronic vein insufficiency correction in patients with lower extremities varicosity and knee osteoarthritis
Introduction. Chronic vein diseases in general and varicose veins of the lower extremities in particular represent a serious medical and social problem.The aim was to study the influence of the therapy of venous outflow disorders on the treatment results of osteoarthritis of the knee joints in patients with varicose veins in combination with osteoarthritis of the knee joints.Materials and methods. The study included 105 patients with varicose veins combined with knee osteoarthritis who had previously received treatment for osteoarthritis of the knee joints but had not received or had received extremely irregular therapy for varicose veins. The follow-up period for the patients was 12 months. The patients underwent the first course of phlebotropic drugs for 2 months from the start of the study. Then this course was repeated twice at 3-month intervals. The standard phlebotropic drug was a micronized purified flavonoid fraction. Compression knitwear was recommended in all patients. Class 2 stockings or tights with an ankle pressure of 23–32 mmHg were used in the vast majority of cases. Treatment of osteoarthritis included the use of nonsteroidal anti-inflammatory drugs, disease-modifying agents (chondroitin sulfate, glucosamine sulfate), and physical therapy.Results. The VCSS scale reduced the degree of chronic venous insufficiency in the clinical group. At inclusion in the study, the average score in the clinical group was 7.1 ± 1.9, after 6 months the result was 6.1 ± 1.5, and after 12 months – 6.0 ± 1.2 points. In the control group, where patients did not receive therapy for varicose veins, there were no dynamics. The results of joint syndrome against the background of correction of venous outflow disturbances – decrease of Leken and WOMAC index values, decrease of pain syndrome according to the visual analogue scale. All this led to a decrease in the patients' need for taking analgesics.Conclusions. Out of 100 patients with joint pathology, 68 patients were diagnosed with varicose veins. These diseases aggravate each other, but we can assume that the venous pathology is primary. A vicious circle is set in motion – progression of osteoarthritis due to the disturbances of venous outflow, and varicosity due to the deterioration of muscular-venous pump functioning.